News Quantified

ADIL – adial pharmaceuticals, inc (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement

Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One

Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]

Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Adial Pharmaceuticals (NASDAQ:ADIL) was given a new $8.00 price target on by analysts at UBS Group AG.

Form 8-K ADIAL PHARMACEUTICALS, For: Feb 23

Form SCHEDULE 13G ADIAL PHARMACEUTICALS, Filed by: ARMISTICE CAPITAL, LLC

Form 8-K ADIAL PHARMACEUTICALS, For: Feb 03

Form 8-K ADIAL PHARMACEUTICALS, For: Jan 05

Form DEF 14A ADIAL PHARMACEUTICALS, For: Feb 26

Top News Gainers

12/13 Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial 35.8%

4/16 Adial Pharmaceuticals Verifies Proprietary Genetic Test in Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial 26.1%

4/22 Form POS AM ADIAL PHARMACEUTICALS, 14.4%

3/26 Adial Pharmaceuticals Receives Issue Notification for Patent Covering AD04 for the Treatment of Opioid Use Disorder 13.0%

12/13 Form 4 ADIAL PHARMACEUTICALS, For: Dec 12 Filed by: Johnson Bankole A. 12.4%

6/6 Adial Pharmaceuticals and Tedor Pharma Announce Collaboration to Manufacture AD04 Through Commercialization 6.8%

3/27 Form 4 ADIAL PHARMACEUTICALS, For: Mar 25 Filed by: Stilley William B. III 6.2%

2/19 Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Bulgaria 6.0%

9/11 Adial Pharmaceuticals Announces Successful Product Retesting of AD04 for Phase 3 Clinical Trial 5.7%

6/13 Adial Pharmaceuticals Receives Notification Prior to Acceptance of Israeli Patent for AD04 in Alcohol Use Disorder 5.6%

Top News Decliners

5/7 Adial Pharmaceuticals Announces Collaboration Agreement with Eurofins for Genetic Biomarker Testing to Support Upcoming Phase 3 Clinical Trial for Alcohol Use Disorder -13.5%

3/20 Form 10-K ADIAL PHARMACEUTICALS, For: Dec 31 -12.2%

2/14 Adial Pharmaceuticals CEO Selected as a Luncheon Keynote Speaker for the 2020 Wall Street Conference and Retreat -9.8%

3/30 Form 4 ADIAL PHARMACEUTICALS, For: Mar 27 Filed by: Newman James W. Jr. -8.2%

3/5 Form 4 ADIAL PHARMACEUTICALS, For: Mar 03 Filed by: Anderson J. Kermit -8.2%

6/9 Adial Pharmaceuticals Inc (NASDAQ: ADIL) was given a new $5.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. -5.6%

6/19 Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare -5.6%

9/5 Adial Pharmaceuticals Completes Key Regulatory Milestone Prior to Commencing European Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder -5.5%

9/11 Adial Pharma up 12% on confirmed product supply for late-stage study [Seeking Alpha] -5.4%

10/29 Adial Completes Final Packaging of AD04 for Shipment to Phase 3 Trial Clinical Sites -5.2%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day